Tracking weight loss to improve cancer detection
Official title: Unintentional Weight Loss and Cancer: A Prospective Trial of Patient-centered Weight Tracking Combined With GRAIL Galleri Testing to Improve Early Detection
Run by Case Comprehensive Cancer Center · NCT05481697 · Data updated 2026-11-12
This study is testing if tracking weight loss in people aged 40 to 80 can help catch cancer earlier using a new blood test.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 40 Years to 80 Years |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Case Comprehensive Cancer Center Academic / other |
| Locations | 1 site (Cleveland, Ohio) |
| Status | Recruiting |
| Started | May 5, 2023 |
| Main results expected | January 1, 2027 |
| Study ends | January 1, 2027 |
| Registry record updated | September 15, 2026 |
| Trial ID | NCT05481697 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals aged 40 to 80 who can use a compatible device for weight tracking and are willing to participate in the study.
✕Probably not a fit
Patients currently diagnosed with cancer or actively trying to lose weight through medications or surgery may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the relationship between unintentional weight loss (UWL) and cancer detection using the GRAIL Galleri test, an investigational pan-cancer early detection test. Participants aged 40 to 80 will track their weight weekly using a Fitbit Aria Smart Scale for three years. Those who experience a weight loss of 5% or more will undergo further assessments, including the GRAIL Galleri test, health history evaluations, and necessary imaging or screenings. The goal is to determine if combining UWL detection with GRAIL testing can enhance early cancer detection rates.
Why it matters
Potential benefit: If successful, this approach could lead to earlier detection of malignancies in patients experiencing unintentional weight loss.
How similar studies have gone: While the specific combination of UWL tracking and GRAIL testing is novel, similar studies have shown promise in early cancer detection methodologies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age range: from 40 to 80 years * Access to a device (cellphone, computer, tablet) that is compatible with the Fitbit Aria Air smart scale utilized in this study * Willing to comply with all study procedures and be available for the duration of the study * Subjects must be mentally competent and must have the ability to understand and the willingness to sign a written informed consent document * Subjects must speak English to maximize chance of understanding the trial rational and study procedures Exclusion Criteria: * Active cancer diagnosis - current diagnosis, currently undergoing cancer treatment, or concluded cancer treatments within 3 years * Actively trying to lose weight with medications or bariatric surgery * Pregnant
Where it's running
-
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States Recruiting
Study contacts
- Principal investigator: Jordan M Winter, MD — University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
- Study coordinator: Jordan M Winter, MD
- Email: Jordan.Winter@UHHospitals.org
- Phone: (216) 844-5777
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Robot-assisted bronchoscopy for peripheral lung lesions: comparing Monarch and ION platforms
Doctors are testing two FDA-cleared robotic bronchoscopy tools to see which more often successfully sample peripheral lung lesions during a bronchoscopy.
-
Safety and preliminary activity of BMS-986504 in unresectable MPNST
A new medicine called BMS-986504 is being tested to see if it is safe and may help people with unresectable malignant peripheral nerve sheath tumors, especially those whose tumors lack MTAP.
-
Wearable sensors and digital health in early cancer trials
This pilot study tests whether wearable activity tracking and electronic patient-reported outcomes can be feasibly used in early-phase cancer trials for adults.
-
HPV DNA-guided chemoradiation with Retifanlimab for locally advanced anal cancer
This study tests whether adjusting chemoradiation doses based on HPV ctDNA results and adding Retifanlimab after CRT can improve outcomes for adults with new, locally advanced anal cancer.
-
MiraBurst to help with changes in taste from cancer treatment
This study tests whether freeze-dried miracle fruit (MiraBurst) can improve taste changes in adults with solid tumors who are undergoing cancer treatment.
-
Memory-avoidance whole brain radiotherapy: trying to protect memory while treating brain metastases
This study tests whether memory-avoidance whole brain radiotherapy with memantine is better at preserving thinking and memory than hippocampal-avoidance whole brain radiotherapy with memantine for adults with brain metastases.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.